Potential clinical utility of ERC-2 yeast phase lysate antigen for antibody detection in dogs with blastomycosis

Abstract Four Blastomyces antigens ERC-2 (B. gilchristii, dog, Wisconsin), B5929 (human, Minnesota), 597 (human, Wisconsin), and T-27 (polar bear, Tennessee) were tested against 31 serum specimens from dogs with blastomycosis and 19 from healthy dogs. All antigens detected antibody; efficacy varied....

Full description

Bibliographic Details
Published in:Medical Mycology
Main Authors: RoyChowdhury, Moytri, Muzzall, Evan, Baumgardner, Dennis J, Kennell, Bryn C, Esterbrook, Arin C, Shurley, Jack F, Scalarone, Gene M
Format: Article in Journal/Newspaper
Language:English
Published: Oxford University Press (OUP) 2018
Subjects:
Online Access:http://dx.doi.org/10.1093/mmy/myy137
http://academic.oup.com/mmy/article-pdf/57/7/893/29186130/myy137.pdf
Description
Summary:Abstract Four Blastomyces antigens ERC-2 (B. gilchristii, dog, Wisconsin), B5929 (human, Minnesota), 597 (human, Wisconsin), and T-27 (polar bear, Tennessee) were tested against 31 serum specimens from dogs with blastomycosis and 19 from healthy dogs. All antigens detected antibody; efficacy varied. ERC-2 showed the highest ELISA mean absorbance value of 3.00 followed by T-27. Test performance varied by sample geographic origin. Further study is needed to determine if ERC-2 antigens may be clinically useful, and whether the combination of the particular fungal species as antigen source, host animal, and the species and geographic location of the patient being tested is important for optimum test characteristics.